Selected research
Market Structure
Global Dolutegravir Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Dolutegravir market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Dolutegravir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Dolutegravir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Dolutegravir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Dolutegravir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Dolutegravir include Shanghai Desano Pharmaceuticals, Mylan, ViiV Healthcare (GSK), LAURUS Labs, Aurobindo Pharma and Adcock Ingram Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Dolutegravir market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Dolutegravir and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Dolutegravir sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dolutegravir market size, projected growth trends, production technologies, key applications, and end-use industries.
Dolutegravir Segment by Company
Shanghai Desano Pharmaceuticals
Mylan
ViiV Healthcare (GSK)
LAURUS Labs
Aurobindo Pharma
Adcock Ingram Limited
Dolutegravir Segment by Type
10mg Tablets
50mg Tablets
Dolutegravir Segment by Application
Prevent HIV Infection Following Potential Exposure
Others
Dolutegravir Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dolutegravir market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dolutegravir and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dolutegravir.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Dolutegravir market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dolutegravir manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Dolutegravir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Dolutegravir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 10mg Tablets
- 50mg Tablets
Applications
- Prevent HIV Infection Following Potential Exposure
- Others
Companies covered
- Shanghai Desano Pharmaceuticals
- Mylan
- ViiV Healthcare (GSK)
- LAURUS Labs
- Aurobindo Pharma
- Adcock Ingram Limited
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Dolutegravir Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Dolutegravir Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Dolutegravir Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Dolutegravir Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Dolutegravir Market Dynamics
- 2.1 Dolutegravir Industry Trends
- 2.2 Dolutegravir Industry Drivers
- 2.3 Dolutegravir Industry Opportunities and Challenges
- 2.4 Dolutegravir Industry Restraints
3 Dolutegravir Market by Manufacturers
- 3.1 Global Dolutegravir Revenue by Manufacturers (2021-2026)
- 3.2 Global Dolutegravir Sales by Manufacturers (2021-2026)
- 3.3 Global Dolutegravir Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Dolutegravir Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Dolutegravir Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Dolutegravir Manufacturers, Product Type & Application
- 3.7 Global Dolutegravir Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Dolutegravir Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Dolutegravir Players Market Share by Revenue in 2025
- 3.8.3 2025 Dolutegravir Tier 1, Tier 2, and Tier 3
4 Dolutegravir Market by Type
- 4.1 Dolutegravir Type Introduction
- 4.1.1 10mg Tablets
- 4.1.2 50mg Tablets
- 4.2 Global Dolutegravir Sales by Type
- 4.2.1 Global Dolutegravir Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Dolutegravir Sales by Type (2021-2032)
- 4.2.3 Global Dolutegravir Sales Market Share by Type (2021-2032)
- 4.3 Global Dolutegravir Revenue by Type
- 4.3.1 Global Dolutegravir Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Dolutegravir Revenue by Type (2021-2032)
- 4.3.3 Global Dolutegravir Revenue Market Share by Type (2021-2032)
5 Dolutegravir Market by Application
- 5.1 Dolutegravir Application Introduction
- 5.1.1 Prevent HIV Infection Following Potential Exposure
- 5.1.2 Others
- 5.2 Global Dolutegravir Sales by Application
- 5.2.1 Global Dolutegravir Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Dolutegravir Sales by Application (2021-2032)
- 5.2.3 Global Dolutegravir Sales Market Share by Application (2021-2032)
- 5.3 Global Dolutegravir Revenue by Application
- 5.3.1 Global Dolutegravir Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Dolutegravir Revenue by Application (2021-2032)
- 5.3.3 Global Dolutegravir Revenue Market Share by Application (2021-2032)
6 Global Dolutegravir Sales by Region
- 6.1 Global Dolutegravir Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Dolutegravir Sales by Region (2021-2032)
- 6.2.1 Global Dolutegravir Sales by Region (2021-2026)
- 6.2.2 Global Dolutegravir Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Dolutegravir Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Dolutegravir Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Dolutegravir Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Dolutegravir Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Dolutegravir Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Dolutegravir Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Dolutegravir Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Dolutegravir Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Dolutegravir Revenue by Region
- 7.1 Global Dolutegravir Revenue by Region
- 7.1.1 Global Dolutegravir Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Dolutegravir Revenue by Region (2021-2026)
- 7.1.3 Global Dolutegravir Revenue by Region (2027-2032)
- 7.1.4 Global Dolutegravir Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Dolutegravir Revenue (2021-2032)
- 7.2.2 North America Dolutegravir Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Dolutegravir Revenue (2021-2032)
- 7.3.2 Europe Dolutegravir Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Dolutegravir Revenue (2021-2032)
- 7.4.2 Asia-Pacific Dolutegravir Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Dolutegravir Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Dolutegravir Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Shanghai Desano Pharmaceuticals
- 8.1.1 Shanghai Desano Pharmaceuticals Company Information
- 8.1.2 Shanghai Desano Pharmaceuticals Business Overview
- 8.1.3 Shanghai Desano Pharmaceuticals Dolutegravir Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Shanghai Desano Pharmaceuticals Dolutegravir Product Portfolio
- 8.1.5 Shanghai Desano Pharmaceuticals Recent Developments
- 8.2 Mylan
- 8.2.1 Mylan Company Information
- 8.2.2 Mylan Business Overview
- 8.2.3 Mylan Dolutegravir Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Mylan Dolutegravir Product Portfolio
- 8.2.5 Mylan Recent Developments
- 8.3 ViiV Healthcare (GSK)
- 8.3.1 ViiV Healthcare (GSK) Company Information
- 8.3.2 ViiV Healthcare (GSK) Business Overview
- 8.3.3 ViiV Healthcare (GSK) Dolutegravir Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 ViiV Healthcare (GSK) Dolutegravir Product Portfolio
- 8.3.5 ViiV Healthcare (GSK) Recent Developments
- 8.4 LAURUS Labs
- 8.4.1 LAURUS Labs Company Information
- 8.4.2 LAURUS Labs Business Overview
- 8.4.3 LAURUS Labs Dolutegravir Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 LAURUS Labs Dolutegravir Product Portfolio
- 8.4.5 LAURUS Labs Recent Developments
- 8.5 Aurobindo Pharma
- 8.5.1 Aurobindo Pharma Company Information
- 8.5.2 Aurobindo Pharma Business Overview
- 8.5.3 Aurobindo Pharma Dolutegravir Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Aurobindo Pharma Dolutegravir Product Portfolio
- 8.5.5 Aurobindo Pharma Recent Developments
- 8.6 Adcock Ingram Limited
- 8.6.1 Adcock Ingram Limited Company Information
- 8.6.2 Adcock Ingram Limited Business Overview
- 8.6.3 Adcock Ingram Limited Dolutegravir Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Adcock Ingram Limited Dolutegravir Product Portfolio
- 8.6.5 Adcock Ingram Limited Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Dolutegravir Value Chain Analysis
- 9.1.1 Dolutegravir Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Dolutegravir Production Mode & Process
- 9.2 Dolutegravir Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Dolutegravir Distributors
- 9.2.3 Dolutegravir Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst